Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain excitatory neurons (183 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 44 | 0.91 |
| pathways Reactome | Reactome did not answer (Reactome: HTTP 521) | 0.00 |
No case: the score is under the bar. Receipt 8728
Sealed predictions
- APBA2 in dopamine neurons, braak-0.56 (p 0.114) → +0.05 (p 0.891)receipt 8736
Swarm cases
receipt 8736: APBA2 in dopamine neurons, braak
- power
- full sample -0.21 (p 0.413, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.413, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.42 (p 0.084, n 18). could be the mix.
- skeptic
- leave-one-out range -0.32 to -0.10, sign flips 0; without severely affected donors -0.21 (p 0.413, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.60 (p 0.0089, n 18) vs -0.21 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for APBA2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up APBA2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.55 p 0.051 (needs p < 2.4e-4)
Receipts
loading the receipts